Company press releases

Displaying 101 - 128 of 128 results
Released Company Title Industry Topic
30 Jun 2022
13:20 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
30 Jun 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Jun 2022
08:00 CEST 		ULTIMOVACS Ultimovacs' UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 May 2022
18:45 CEST 		ULTIMOVACS Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
12 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: First quarter 2022 result presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
22 Apr 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Share Option Program 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2022
11:14 CEST 		ULTIMOVACS Ultimovacs ASA - Annual General Meeting held on 21 April 2022 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Apr 2022
19:00 CEST 		ULTIMOVACS Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Apr 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting 20103010 Biotechnology Total number of voting rights and capital
30 Mar 2022
11:00 CEST 		ULTIMOVACS Ultimovacs to host Investor Days 2022: Meet the Team 20103010 Biotechnology Non-regulatory press releases
25 Mar 2022
08:47 CET 		ULTIMOVACS Correction: Ultimovacs ASA: Annual Report 2021 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Mar 2022
07:50 CET 		ULTIMOVACS Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Mar 2022
07:30 CET 		ULTIMOVACS Ultimovacs ASA: Annual Report 2021 20103010 Biotechnology Annual financial and audit Reports
21 Mar 2022
08:00 CET 		ULTIMOVACS Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 Mar 2022
16:30 CET 		ULTIMOVACS Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting 20103010 Biotechnology Non-regulatory press releases
17 Feb 2022
13:18 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
17 Feb 2022
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Fourth quarter 2021 result presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 Feb 2022
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation 20103010 Biotechnology Non-regulatory press releases
03 Feb 2022
08:00 CET 		ULTIMOVACS Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Dec 2021
09:20 CET 		ULTIMOVACS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
15 Dec 2021
08:00 CET 		ULTIMOVACS First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
02 Dec 2021
19:00 CET 		ULTIMOVACS Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
02 Dec 2021
16:30 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
29 Nov 2021
20:15 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
25 Nov 2021
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification for close associate 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State